; and (D) other relevant qualifications, as determined by the Secretary; (2) select at least one institution with the capability to handle secure and classified information, as appropriate; and (3) prioritize institutions most likely to aid in the advancement and innovation of the medical countermeasure products, the manufacturing processes for such products, and the execution and design of clinical trials. (c) Center activities The Center established under subsection (a) shall assist public and private entities in accelerating nonclinical research discoveries with respect to medical countermeasures through advanced development and clinical trials. The activities of the Center may include— (1) advanced process development and pilot manufacturing to support clinical trials; (2) technical assistance; (3) contract award management; (4) referral and coordination with potential manufacturing partners; (5) regulatory assistance; (6) technology transfer; and (7) program management. (d) Eligible products A drug or device (including a combination of one or more drugs or devices) is eligible for consideration and referral by the Director of BARDA to the Center if such drug or device incorporates a novel technology, or uses an established technique or technology in a novel way, that will substantially— (1) further development of a drug or device of interest; (2) fulfil an unmet need; or (3) develop the manufacturing process for a drug or device. (e) International coordination The Director of BARDA, in collaboration with the Assistant Secretary for Global Affairs and the Center established under subsection (a), shall coordinate, as appropriate, with international partners to enhance global health security by encouraging other initiatives, similar to the program described in subsection (a), under which international advanced development networks support an expanded worldwide strategy for vaccine, drug, device, and other countermeasure research, development, and manufacturing. .